The disclosure relates to ophthalmic composition comprising polyoxyethylene (80) sorbitan monooleate, carboxymethylcellulose sodium, glycerin, boric acid, acrylates/C10-30 alkyl acrylate crosspolymer, castor oil, erythritol, levocarnitine, sodium hydroxide, and water. The composition may further comprise stabilized oxychloro complexes. The disclosure also relates to a method of treating, diagnosing, curing, mitigating or preventing dry eye syndrome comprising administering an effective amount of said composition.